BeiGene, Ltd. (ONC)vsAlaunos Therapeutics Inc (TCRT)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
TCRT
Alaunos Therapeutics Inc
$3.01
-4.14%
HEALTHCARE · Cap: $7.01M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 89050450% more annual revenue ($5.34B vs $6,000). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
TCRT
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for TCRT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Revenue surging 100.0% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -145.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : TCRT
The strongest argument for TCRT centers on Revenue Growth, PEG Ratio, Price/Book. Revenue growth of 100.0% demonstrates continued momentum. PEG of 0.58 suggests the stock is reasonably priced for its growth.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : TCRT
The primary concerns for TCRT are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
TCRT is growing revenue faster at 100.0% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 38/100) and 32.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Alaunos Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?